(1 month, 3 weeks ago)
Lords ChamberMy Lords, I thank the noble Viscount, Lord Stansgate, for securing this important debate. We on this side feel fortunate to have the Minister in his new role. His previous role in this area is very relevant and we welcome him to his first debate. We are delighted to have someone with such knowledge in his position.
I hope to conduct my speech in the constructive manner proposed by the noble Viscount. We all know and recognise the incredible impact that science and technology has in this country. The 4% that it is estimated to add to the economy is a massive boost. We can all point to massive scientific successes. One of the biggest illustrations of this is that, of the 10 Formula 1 teams, six are based in the UK. You cannot get more cutting-edge science and technology than Formula 1. We have those that noble Lords will know—great British names such as McLaren, Williams and Aston Martin—but also other well-known brands such as Mercedes, Renault and Red Bull. Yes, those foreign brands’ Formula 1 teams are located in the UK because they know that we are the best and most cutting-edge.
I will take the limited time available to talk about the area I know best from my former health role: life sciences. We have some fantastic examples in this field too. Google’s AlphaFold project will see many breakthroughs. The Government’s involvement in Covid and the Minister’s involvement in the Moderna deal that followed are a good example of putting long-term relationships in place.
But what I have seen all too often at first hand is what I call the UK disease: we are very good at innovation but pretty poor at the rollout. I saw this particularly in medtech. The joke I always heard is that the NHS has more pilots than British Airways. Those pilots were good in their innovation but so often fell down when it came to rolling out across the network. We would often see them lost to the US, which would come in with the funding and the rollout programme, and we would see a brain drain of our expertise.
One of the last things we tried to do was introduce what we called a medtech rules-based pathway, which tried to provide a pathway so that there was a way that exciting parts of medical technology could be rolled out through the NHS under a set of well-known rules. We were consulting on that around the time we left government. I would be pleased if the Minister could update me on the findings—it would be super to have that by letter if he does not have them to hand.
Another area was the data for R&D. As we all know, AI is only as good as the data that it comes from. We are fortunate in the medical space to have probably the best data in the world, as I have been told by many people, dating back to 1948—primary care, secondary care and biobank data. We were working on a project to bring this all together to create the possibility of a Silicon Valley of life sciences. I would be delighted to hear where we are in the progress of that project.
I end on a note of caution. A £1 investment achieving a £3 to £4 return is a case of modern-day alchemy, but it requires deep pockets, long-term investment and hard work to achieve those rewards. Anything that diminishes those rewards will be a threat. My concerns about the latest Budget, dare I say, are the moves on tax increases. The crowding out of private finance that the OBR is concerned about puts this at risk, so I hope that we are careful and make sure that we do not kill the golden goose that we have in this space.
(1 month, 3 weeks ago)
Lords ChamberUniversities have been under pressure, as the noble Lord knows, for a number of reasons, including student fees, overseas student numbers and questions about the full economic costs of research in addition to inflation. These are all important areas that will need to be looked at. It is worth remembering that, over the years, roughly one MRC unit per year has closed and a new one has started. This process is part of that continuing change, which I believe is important to make sure that we stay at the cutting edge. As part of that, the staff on the new wards will be fully paid. The principal investigator salary is the one that will have to be picked up in part by a host institution or by other grants coming in to provide support.
Given the well-known fact that every £1 of government investment generates a return of £3 to £4 to the UK economy, does the Minister agree that any move to reduce government R&D spend or to close specialist research centres would be an act of economic self-harm, in direct contradiction to the Government’s claim to prioritise economic growth?
The noble Lord will be unsurprised that I am a strong supporter of R&D funding and know the importance of its links to economic growth. It is crucial that we look at the spread of R&D funding. It is the case that it will be necessary, from time to time, to shut some things and open new things—that has always been the case—otherwise things become ossified and you never end up with new programmes. I fully expect there to be a continued pattern of renewed support for some areas and a closing down of others. What is important in the context of this particular scheme is that the same proportion of MRC funding will be spent on these new centres as was spent on the old units and centres.
(2 months, 2 weeks ago)
Lords ChamberThe noble Lord is quite right that the numbers are looking more promising for 2024, particularly in the European Research Council mono-beneficiary schemes. In the collaborative and industry schemes, things still look fairly flat, although there are some examples of very good progress. In the European rail project, 61% in the most recent round had a UK participant and five out of the seven successful bids had UK participants, so there is some progress. We are doing a number of things: there is an increased communications campaign, the last one having led to a substantial increase of 64,000 hits on the UK Horizon website; there are roadshows, most recently in Birmingham and Glasgow and soon in Northern Ireland and Wales; there are pump priming grants, which have led to an ability to get money to work out how to make applications to Horizon programmes—I am pleased to say that of those people who received those grants and put in applications, 100% were eligible. Finally, European network programmes are being set up to link UK academic teams and industry to European teams in the most successful countries.
I also welcome the Minister to answering his first Question—I know what it feels like. Following on from the last question, obviously we want to maximise participation and I am pleased to hear that the roadshow that we introduced is continuing to be rolled out. Are there particular sectors that we need to focus on in the outreach? I hear that the SME sector is particularly underrepresented.
I thank the noble Lord for his question. He is right that the SME sector is underrepresented, and there is a specific effort to increase its ability to engage and to raise awareness within it. We hope that will be a major part of the European networking programme as well.